A close collaboration between our population health team and secondary care has resulted in targeted, transformative care for a group of patients:
The development of innovative treatments using biotechnological methods has transformed the management of numerous modern-day conditions. Patients with diabetes, various cancers, and those benefiting from measles or HPV vaccines are all examples of people whose lives have been improved by a class of drugs known as biologics. Typically administered via injection in a hospital setting, these advanced therapies hold significant promise for patients with severe asthma.
Dr. Peter Creber, consultant in respiratory medicine at Southmead Hospital in Bristol, frequently supports patients grappling with acute asthma. They often require multiple GP appointments and are at higher risk of A&E visits and unplanned hospital admissions – a situation that negatively impacts their well-being and places a significant financial burden on the healthcare system. While biologics offer the potential for substantial improvement in these patients’ symptoms, prescription is currently limited to secondary care. This raises the crucial question: how can patients within the Bristol, North Somerset and South Gloucestershire (BNSSG) area be identified and offered these potentially life-changing treatments when their primary health records are kept by their GP?
To address this challenge, Dr. Creber contacted One Care, a collaboration that quickly revealed a pathway to support patients severely affected by their asthma. Currently 37 practices within BNSSG have agreed to participate in this work, and collaboratively suitable patients for biologic treatment have been identified. This process involved reviewing specific key health indicators within the patient record, as these medications are not appropriate for all individuals with asthma.
Dr. Creber said: “Once a patient has been identified as eligible, the administration of the biologic injection is straightforward, and the positive effect on their physical well-being is often dramatic.”
A single injection can provide relief for up to five years, offering patients the opportunity to significantly improve their quality of life. This not only reduces the need for urgent GP appointments, freeing up valuable primary care resources, but also minimizes unplanned hospital admissions.
One Care’s population health analyst, Phil Gladwin, said: ‘I’m delighted to have been involved in a project which has supported patients with severe asthma, and potentially freed up urgent GP appointments for other patients.’
This successful collaboration between secondary care and primary care, facilitated by One Care, exemplifies how integrated working can deliver optimal care for patients with severe asthma, resulting in positive outcomes for both the individuals and the wider healthcare system. Dr. Creber and the team continue to identify and support eligible patients across BNSSG, demonstrating the power of joined-up healthcare in transforming lives.
If you would like to find out more – or would like to discuss how our population health analysts can help target patient groups – please email business.intelligence@onecare.org.uk